

2022-9-2 Executive Team Meeting notes

Date

02 Sep 2022

Attendees

Committee Member	Present	Absent
Kuffel, Gina (NIH/NCI) [C]	X	
Unknown User (leblancak)	X	
Otridge, John (NIH/NCI) [C]		
Kim, Erika (NIH/NCI) [E]	X	
Sommers, Connie (NIH/NCI) [E]		
Debbie Knapp		X
Toby Hecht	X	
Unknown User (parchmentr)		

Goals

- Discuss updates to ICDC and define emerging strategies and priorities

SharePoint Site

<https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups>

Outstanding Action Items

- ☒ Toby to work on outline for RFI

Agenda

Item	Who	Talking Points
DGAB Updates	Kuffel, Gina (NIH/NCI) [C]	<ul style="list-style-type: none">• 33 TB of data are now available in ICDC (five-fold increase since January)• TCL01: A multi-omics analysis of canine cancer cell lines<ul style="list-style-type: none">◦ File transfer is complete◦ Metadata loaded onto Dev tier◦ Indexing completed by DCF team◦ Pending release record is visible on production◦ Study is under formal testing by our team• PRECINCT has used templates available from the ICDC Data Model Explorer (DME) for the first ever load of a study via submitter-generated loading files<ul style="list-style-type: none">◦ Initial version of data is available in Dev tier◦ Data includes program, study, and and complete case records.◦ No sample records or files derived from samples yet.• Will has volunteered his time to create a scientific use case from ICDC data (respond to RFI)• DGAB approved new data submission request from Dawn Duval's group: "Immune Pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma". (26 tumor normal pairs)• Kick-off call for the PanCan study

BPSC Updates	Kuffel, Gina (NIH/NCI) [C]	<ul style="list-style-type: none"> • 2022 BPSC Review Article <ul style="list-style-type: none"> ◦ Outline completed ◦ Section drafts are completed ◦ Cheryl London is in the process of editing
August Steering Committee Updates	Unknown User (parchmentr)	<ul style="list-style-type: none"> • Minutes to be posted • Next meeting is September 21st
ICDC Site Updates	Kuffel, Gina (NIH/NCI) [C]	<ul style="list-style-type: none"> • Next software release targets October 13th <ul style="list-style-type: none"> ◦ Multi-file select for JBrowse ◦ Elasticsearch ◦ Data Model Navigator <ul style="list-style-type: none"> ▪ ReadMe file and viewing modal ▪ TSV & JSON downloads of controlled vocabularies for properties with enumerated values ▪ Node-specific tsv downloads ▪ Faceted search augmented to include props featured on the UI ▪ File transfer manifest to enable seamless file hand-offs
ICDC Next Phase Planning	Unknown User (hechtt)	<ul style="list-style-type: none"> • Request for Information (RFI) has been submitted • 2 focus groups met <ul style="list-style-type: none"> ◦ Ideas from the ICDC brainstorming sessions final.docx

Minutes (Not Verbatim)

TH- Possible COI with people working on the RFI and then responding to the RFI. Dr. Doroshow signed off on RFI. Unless there are issues noted the RFI should be published in ~ 2 weeks. Many ideas came from initial focus groups.

JO- What type of plans can be put in place to advertise the RFI? Can we leverage NCI social media?

TH- We can send to anyone we want, including Cancer Center Directors, they have collaborations with vet clinic schools, some of the foundations.

AL- Circulate to PRECINCT as well.

TH- Deadline for response is Dec. 1st.

AL- Giving presentation to the children's oncology group. Touched base with CIN and PRECINCT. The talk is osteo-focused.

Previous ICDC Use Cases from Steering Committee

1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
 1. Search for conserved mutations between canine and human tumors
 2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
 5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
 6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
 7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
 8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

Previous Meeting Minutes (Not Verbatim)

Toby- Understanding of RFI is to go out ask for people doing comparative oncology across humans and dogs research to come up with questions or case studies or hypotheses that can leverage data in the ICDC to answer these question to expose gaps of data to inform the type of data we would like to source in the future.

DK- To identify key questions and if ICDC can help to answer these questions.

Toby- Who will be the PoC? I will do an outline of this and then circulate to this to the Executive Team.

JO - Executive TEam and then polish for broader dissemination to the Steering Committee.

Toby- We can send out to the Cancer Centers

AL - We can encourage all to share broadly

Action item